Pamela N. Münster

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of San Francisco · ORCID：0000-0002-2074-0984

发表论文 744 篇 · 总被引 20164 次 · h-index 67

代表论文

• Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study (2025 · Journal of Clinical Oncology · 被引 27)
• The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial (2025 · Clinical Cancer Research · 被引 7)
• Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer (2025 · npj Breast Cancer · 被引 3)
• Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). (2026 · Journal of Clinical Oncology · 被引 2)
• Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer (2025 · Breast Cancer Research · 被引 1)
• Supplementary Table S3 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies (2026)